Kenya vs Kyrgyzstan: Average cost of multi drug-resistant tuberculosis treatment
Kenya
1,800 constant 2022 US$
in 2024
Kyrgyzstan
1,607 constant 2022 US$
in 2022
Kenya rank
26th
Kyrgyzstan rank
29th
Average cost of multi drug-resistant tuberculosis treatment over time
- Kenya
- Kyrgyzstan
How they compare
Kenya currently reports 1,800 constant 2022 US$ against 1,607 constant 2022 US$ in Kyrgyzstan, a difference of 193 constant 2022 US$.
That makes Kenya's figure about 1.1 times Kyrgyzstan's.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Kyrgyzstan ahead.
Kenya ranks 26th and Kyrgyzstan ranks 29th of 92 countries.
Across the 2 decades both report, Kenya averaged higher in 1 and Kyrgyzstan in 1.
Head to head by decade
| Decade | Kenya | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,883 constant 2022 US$ | 2,218 constant 2022 US$ | 665.67 constant 2022 US$ | Kenya |
| 2020s | 1,644 constant 2022 US$ | 1,761 constant 2022 US$ | 116.67 constant 2022 US$ | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Kenya or Kyrgyzstan?
- Kenya, at 1,800 constant 2022 US$ against 1,607 constant 2022 US$ in Kyrgyzstan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Kenya and Kyrgyzstan?
- 193 constant 2022 US$, with Kenya ahead.
- How many years of comparable data are there for Kenya and Kyrgyzstan?
- 6 years are reported by both, from 2017 to 2022.
- How do Kenya and Kyrgyzstan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Kenya ranks 26th and Kyrgyzstan ranks 29th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.